Compositions and methods for promoting wound healing and tissue repair
OwnerHynda Kleinman, Allan Goldstein +2inventors
InventorsHynda Kleinman, Allan Goldstein, Katherine Malinda, Gabriel Sosne
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for promoting tissue repair, angiogenesis and cell migration. The method of the invention utilizes thymosin β4 (Tβ4) peptide to promote tissue repair, angiogenesis and cell migration. The invention further relates to modulating Tβ4 activity in tissues.
Claims67
A method for promoting wound healing in a subject in need of such treatment comprising administering to the subject a wound-healing effective amount of a composition containing a wound healing polypeptide comprising the amino acid sequence LKKTET and conservative variants thereof having wound healing activity.
A method for promoting wound healing in a subject in need of such treatment comprising administering to the subject a wound-healing effective amount of a composition containing thymosin β4 or an isoform of thymosin β4.
A method for promoting wound healing in a tissue comprising contacting the tissue with a therapeutically effective amount of a composition containing a wound healing polypeptide comprising the amino acid sequence LKKTET and conservative variants thereof having wound healing activity.
24 The method of claim 23, wherein the wound healing polypeptide is thymosin β4 or an isoform of thymosin β4.
The method of claim 24, wherein the composition further contains an agent that stimulates the production of thymosin β4 peptide.
A method of inhibiting wound healing in a subject, comprising administering to the subject a composition containing an agent which regulates thymosin β4 activity.
A method of diagnosing a pathological state in a subject suspected of having pathology characterized by a wound healing disorder associated with thymosin β4, comprising:
- obtaining a sample suspected of containing thymosin β4 from the subject;
- detecting a level of thymosin β4 in the sample;
- and
- comparing the level of thymosin β4 in the sample to the level of thymosin β4 in a normal standard sample.
A method for ameliorating a wound healing disorder associated with thymosin β4, comprising treating a subject having the disorder, at the site of the disorder, with an agent which regulates thymosin β4 or the activity of a thymosin β4 isoform.
48 The method of claim 47, wherein the thymosin β4 regulating agent is an antagonist of thyrnosin β4 peptide.
The method of claim 48, wherein the antagonist is an antibody which specifically binds to thymosin β4 peptide.
A method for identifying a compound which modulates wound healing, angiogenesis or cell migration activity, comprising contacting thymosin β4 or an isoform of thymosin β4 with a compound suspected of having thymosin β4 modulating activity and detecting an effect on thymosin β4 or thymosin β4 isoform activity.
51 The method of claim 50, wherein the compound is an agonist of thymosin β4 activity.
53 A method of promoting epithelial cell migration, comprising contacting an epithelial cell with a composition comprising thymosin β4 or an isoform of thymosin β4.
The method of claim 53, wherein the epithelial cell is a skin cell.
The method of claim 53, wherein the epithelial cell is a corneal epithelial cell.
The method of claim 53, wherein the contacting is in vivo.
The method of claim 53, wherein the contacting is in vitro or ex vivo.
The method of claim 53, wherein the composition is selected from the group consisting of a gel, cream, paste, lotion, spray, suspension, dispersion, salve, hydrogel, ointment, and a biocompatible matrix.
A pharmaceutical composition comprising wound healing polypeptide comprising the amino acid sequence LKKTET and conservative variants thereof having wound healing activity, and a pharmaceutically acceptable carrier.
63 The pharmaceutical composition of claim 62, wherein the wound healing polypeptide is thymosin β4 or an isoform of thymosin β4.
Dependencies are inferred from the claim text.